Owe J F, Sanaker P S, Naess H, Thomassen L
Section for Neurology, Institute of Clinical Medicine, University of Bergen, Bergen, Norway.
Acta Neurol Scand. 2006 Nov;114(5):354-7. doi: 10.1111/j.1600-0404.2006.00674.x.
Intravenous thrombolysis with recombinant tissue plasminogen activator (tPA) for acute ischemic stroke has been proved to be effective when given within 3 h of onset of stroke symptoms. Partly due to this time limit, less than 10% of stroke patients are treated with tPA. This study assessed the potential for increased tPA utilization with a theoretical time limit of 6 h.
A total of 117 patients admitted with a diagnosis of acute cerebrovascular disease were prospectively registered over a 3-month period, with emphasis on timing and criteria for tPA treatment.
Eighty-eight of 117 patients (75%) had an acute ischemic stroke. Of these, 23% arrived within 3 h, 8% within 3-6 h, and 69% later than 6 h after symptom onset. Of the seven patients in the 3-6 h group, only one had time delay as the only contraindication to tPA.
This study suggests that reducing patient delay, rather than increasing the time limit for thrombolytic treatment, may increase the frequency of tPA utilization. Changing time limits for thrombolysis may reduce time delay from stroke onset to arrival in hospital due to more rapid handling of patients by the emergency medical services.
对于急性缺血性卒中,在卒中症状发作3小时内给予重组组织型纤溶酶原激活剂(tPA)进行静脉溶栓已被证明是有效的。部分由于这个时间限制,接受tPA治疗的卒中患者不到10%。本研究评估了将理论时间限制延长至6小时来提高tPA利用率的可能性。
在3个月的时间里前瞻性登记了总共117例诊断为急性脑血管疾病的患者,重点关注tPA治疗的时间和标准。
117例患者中有88例(75%)为急性缺血性卒中。其中,23%在症状发作3小时内到达,8%在3 - 6小时内到达,69%在症状发作6小时后到达。在3 - 6小时组的7例患者中,只有1例因时间延迟是tPA治疗的唯一禁忌证。
本研究表明,减少患者延误,而非增加溶栓治疗的时间限制,可能会提高tPA的使用频率。改变溶栓时间限制可能会减少从卒中发作到入院的时间延迟,因为紧急医疗服务对患者的处理更加迅速。